^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    BRMS1 (BRMS1 Transcriptional Repressor And Anoikis Regulator)

    i
    Other names: BRMS1, BRMS1 Transcriptional Repressor And Anoikis Regulator, Breast Cancer Metastasis Suppressor 1, Breast Cancer Metastasis-Suppressor 1, DKFZP564A063
    Associations

    News

    Trials
    20d
    Expression patterns of bone morphogenetic protein 7 (BMP7) and its prognostic roles in neuroblastoma: An integrated bioinformatics analysis. (PubMed, PLoS One)
    BMP7 was a prognostic maker of neuroblastoma.
    Journal
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • BRMS1 (BRMS1 Transcriptional Repressor And Anoikis Regulator) • BMP8B (Bone Morphogenetic Protein 8b)
    |
    MYCN amplification
    28d
    A proteogenomic atlas of 1032 brain metastases identifies molecular subtypes, immune landscapes, and therapeutic vulnerabilities. (PubMed, Nat Commun)
    Patient-derived organoids coupled with targeted drug screening indicate subtype-specific molecular dependencies and putative targets, notably mTOR signaling activation in BrMS3 and CDK4/6 axis activation in BrMS4, while BrMS1 and BrMS2 display distinct radiobiologic and immunologic signatures. This atlas provides a rigorous classification framework of BrMs and offers insights into subtype-specific molecular vulnerabilities.
    Journal
    |
    CDK4 (Cyclin-dependent kinase 4) • BRMS1 (BRMS1 Transcriptional Repressor And Anoikis Regulator)
    3ms
    BRMS1L promotes chemotherapy sensitivity by inhibiting autophagy in breast cancer. (PubMed, Front Genet)
    To our knowledge, this is the first study that showed that reduced BRMS1L expression is associated with poor response to neoadjuvant chemotherapy and unfavorable prognosis in breast cancer patients. Our findings reveal a novel role of BRMS1L in chemosensitivity and highlight its potential clinical application in the treatment of breast cancer.
    Journal
    |
    ATG5 (Autophagy Related 5) • BRMS1 (BRMS1 Transcriptional Repressor And Anoikis Regulator)
    4ms
    In vitro and in silico analysis of the anti-proliferative effects of Spirulina platensis on A549 lung cancer cells. (PubMed, Sci Rep)
    In addition to the kinetic and MAP pathways, docking analysis confirmed that S. platensis binds with the highest affinity to the predicted active sites of the tumor receptor IL-F3, thereby validating its antitumor activity. In conclusion, great suppression in the virulence of lung cancer was reported following treatment with S. platensis, illustrating its suspected mechanism of action, safety profile, kinetic properties, molecular docking results, toxicity, and internal pathways.
    Preclinical • Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BAX (BCL2-associated X protein) • BRMS1 (BRMS1 Transcriptional Repressor And Anoikis Regulator) • MTUS1 (Microtubule Associated Scaffold Protein 1) • SHOX2 (SHOX Homeobox 2)
    7ms
    BRMS1 suppresses the PI3K/AKT/mTOR pathway to regulate autophagy in multiple myeloma. (PubMed, Leuk Lymphoma)
    Targeting BRMS1-mediated autophagy may provide a novel therapeutic approach for MM treatment and addressing disease progression. This study offers new insights into MM pathogenesis and potential strategies for improving patient outcomes.
    Journal
    |
    BRMS1 (BRMS1 Transcriptional Repressor And Anoikis Regulator)
    10ms
    Prognostic impact of anoikis-related genes in low-grade glioma: A bioinformatics and experimental study. (PubMed, Technol Health Care)
    Drug sensitivity screening identified potential drugs with clinical efficacy, such as cisplatin, doxorubicin, erlotinib, and etoposide. Experimental validation confirmed the downregulation of prognosis-related risk genes for anoikis in human glioma cell lines, inhibiting cell anoikis.ConclusionThis study provides insights into the molecular characteristics and clinical importance of disruption-induced anoikis in low-grade glioma. The findings contribute to the understanding of glioma progression and offer potential therapeutic targets.
    Journal
    |
    NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CAV1 (Caveolin 1) • BRMS1 (BRMS1 Transcriptional Repressor And Anoikis Regulator) • ITGB1 (Integrin Subunit Beta 1)
    |
    cisplatin • erlotinib • doxorubicin hydrochloride • etoposide IV
    10ms
    Molecular docking analysis of pyrrole derivatives with different breast cancer targets. (PubMed, Bioinformation)
    Molecular Dynamic results show that significant higher binding energy for Reverb alpha + SR9009 complex found to be -220.618 +/- 19.145 kJ/mol compared to Reverb alpha + Doxorubicin complex found to be -154.812 +/- 18.235 kJ/mol. Molecular docking and dynamics analysis show that SR9009 is a potential drug candidate targeting Reverb alpha for anti-breast cancer activity.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • BRMS1 (BRMS1 Transcriptional Repressor And Anoikis Regulator) • NR1D1 (Nuclear Receptor Subfamily 1 Group D Member 1)
    |
    doxorubicin hydrochloride
    11ms
    Gene expression profile of anoikis reveals new subtypes of liver cancer and discovery of therapeutic targets and biomarkers. (PubMed, Sci Rep)
    Conversely, subtype C2 patients showed higher expression of NTRK2, STAT3, SIK1, AKT1, and EGFR, suggesting these genes as promising therapeutic targets for C2 subtype liver cancer. Furthermore, employing Weighted Correlation Network analysis, machine learning models, and experimental validation, we identified NPY1R and HGF as potential biomarkers for the diagnosis and treatment of liver cancer.
    Journal • Gene Expression Profile
    |
    EGFR (Epidermal growth factor receptor) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CASP8 (Caspase 8) • NPY1R (Neuropeptide Y Receptor Y1) • BRMS1 (BRMS1 Transcriptional Repressor And Anoikis Regulator) • PTK2 (Protein Tyrosine Kinase 2) • SIK1 (Salt Inducible Kinase 1)
    11ms
    Estradiol conjugation to estrogen receptorα upregulates Brms1 expression mediating M2 polarization of alveolar macrophages and exacerbating airway inflammation in asthmatic mice. (PubMed, Mol Immunol)
    The use of ERα antagonist AZD9496 reduced the effect of E2 on the promotion of M2 polarization in AMs...Interference with Brms1 mRNA production reduced the gene expression of Arg1 and YM1 in AMs undergoing M2 polarization after E2 stimulation. In summary, E2 exacerbates airway inflammation in asthmatic mice and binds to ERα, upregulating Brms1 expression and mediating M2 polarization of AMs.
    Preclinical • Journal
    |
    ER (Estrogen receptor) • ARG1 (Arginase 1) • MRC1 (Mannose Receptor C-Type 1) • BRMS1 (BRMS1 Transcriptional Repressor And Anoikis Regulator)
    |
    AZD9496
    over1year
    Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment. (PubMed, Front Oncol)
    AXL and PIM-1 expression detected in CTCs during treatment suggesting new possible therapeutic strategies. Our results reveal that comprehensive liquid biopsy analysis can efficiently represent the heterogeneous molecular landscape and provide prominent information on subsequent treatments for NSCLC patients at PD since druggable molecular alterations were detected in CTCs.
    Journal • Liquid biopsy • PD(L)-1 Biomarker • IO biomarker • Biopsy
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • AXL (AXL Receptor Tyrosine Kinase) • B2M (Beta-2-microglobulin) • FOXA1 (Forkhead Box A1) • PIM1 (Pim-1 Proto-Oncogene) • VIM (Vimentin) • ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1) • KRT19 (Keratin 19) • RASSF1 (Ras Association Domain Family Member 1) • WIF1 (WNT Inhibitory Factor 1) • BRMS1 (BRMS1 Transcriptional Repressor And Anoikis Regulator)
    |
    PD-L1 expression • BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • HER-2 amplification • PIK3CA mutation • BRAF V600 • MET amplification • EGFR T790M • MET mutation • KRAS G12 • EGFR mutation + PIK3CA mutation • HER-2 amplification + PD-L1 expression • VIM expression • HER-2 amplification + MET amplification • RASSF1 methylation
    |
    Tagrisso (osimertinib)
    over1year
    Anti-metastatic Effects of Bee Venom and Melittin in Breast Cancer Cells by Upregulation of BRMS1 and DRG1 Genes. (PubMed, Chem Biol Drug Des)
    Selective cytotoxicity of bee venom and melittin was found to be higher as compared to cisplatin...WNT7B was downregulated in bee venom-treated breast cancer cells. Results suggested that bee venom/melittin exerted antimetastatic effects primarily through upregulation of BRMS1, DRG1, and KAI1/CD82, and downregulation of WNT7B.
    Journal • Metastases
    |
    EGFR (Epidermal growth factor receptor) • NDRG1 (N-Myc Downstream Regulated 1) • BRMS1 (BRMS1 Transcriptional Repressor And Anoikis Regulator) • WNT7B (Wnt Family Member 7B)
    |
    CD8 expression
    |
    cisplatin
    over1year
    Exploring the prognostic value of BRMS1 + microglia based on single-cell anoikis regulator patterns in the immunologic microenvironment of GBM. (PubMed, J Neurooncol)
    This pioneering study used NMF-based analysis to reveal the important predictive value of anoikis-regulated TME in GBM for prognosis and immunotherapeutic response. BRMS1 + microglial cells provide a new perspective for a deeper understanding of the immunosuppressive microenvironment of GBM and could serve as a potential therapeutic target in the future.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • SPP1 (Secreted Phosphoprotein 1) • BRMS1 (BRMS1 Transcriptional Repressor And Anoikis Regulator)